The FDA has released a draft guidance covering the development, trial design, testing and approval pathways for neurodegenerative disease gene therapies. The guidance, which applies to human gene treatments for both pediatric and adult populations, underlines the importance of communicating with the FDA before submitting an investigational new drug application.